All In Biotech

Drug Trial Radar · NCT04034823

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

KN035, a Single Domain PD-L1 Subcutanuous Injection Antibody, in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

59

Planned (sponsor's estimate)

Start

Sep 1, 2019

Primary completion

Jan 1, 2021

Study completion Jan 1, 2022

Sponsor

Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single arm phase II trial to evaluate the efficacy, safety and tolerability of KN035 in combination with trastuzumab and docetaxel. Eligible patient will be enrolled and receive protocol defined therapies until progressive disease, unacceptable toxicity or withdrawal of informed consent. Tumor assessment will be performed according to RECIST 1.1 criteria.

Conditions

  • HER2-positive Breast Cancer

Interventions

  • KN035Biological

    KN035 5 mg/kg s.c. Q3W

  • TrastuzumabBiological

    8 mg/kg IV loading followed by 6 mg/kg Q3W IV

  • DocetaxelDrug

    100 mg/m2 Q3W IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective responseTime frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.